Overview

Letrozole in Uterine Leiomyosarcoma

Status:
Not yet recruiting

Trial end date:
2028-10-30

Target enrollment:

Participant gender:

Summary

This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.

Phase:

Phase 2

Details

Lead Sponsor:

GOG Foundation

Treatments:

Letrozole